Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity

Despite a positive Phase III readout for izokibep in hidradenitis suppurativa, Acelyrin Inc. (NASDAQ:SLRN) is suspending further development in the indication to extend the company’s cash runway and prioritize development of another program. The biotech said the IL-17A inhibitor met the primary endpoint of HiSCR75 with 33% of treated HS patients achieving the endpoint vs. 21% for placebo at week 12.

The company said that the data support approval for the setting, but that further development will be suspended as “a program of this breadth and size is best brought to market by a larger organization.” ...